<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12523">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476957</url>
  </required_header>
  <id_info>
    <org_study_id>Version 1.0 - 12 April 2007</org_study_id>
    <nct_id>NCT00476957</nct_id>
  </id_info>
  <brief_title>Randomized Study Comparing Endeavor With Cypher Stents (PROTECT)</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>PROTECT Trial: Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Vascular</source>
  <oversight_info>
    <authority>Argentina: Human Research Bioethics Committee</authority>
    <authority>Australia: Human Research Ethics Committee</authority>
    <authority>Austria: Ethikkommission</authority>
    <authority>Belgium: Institutional Review Board</authority>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <authority>Canada: Canadian Institutes of Health Research</authority>
    <authority>China: Ethics Committee</authority>
    <authority>Finland: Ethics Committee</authority>
    <authority>France: Institutional Ethical Committee</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Greece: Ethics Committee</authority>
    <authority>Hong Kong: Ethics Committee</authority>
    <authority>India: Institutional Review Board</authority>
    <authority>Ireland: Medical Ethics Research Committee</authority>
    <authority>Israel: Ethics Commission</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Jordan: Ethical Committee</authority>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>New Zealand: Institutional Review Board</authority>
    <authority>Norway:National Committee for Medical and Health Research Ethics</authority>
    <authority>South Africa: National Health Research Ethics Council</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <authority>Switzerland: Ethikkommission</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PROTECT TRIAL is a randomized stent trial with 8800 patients in approximately 200
      hospitals, which is designed to evaluate whether the Endeavor stent PROTECTS against late
      stent thrombosis resulting in less deaths and myocardial infarctions.

      Study Stents:

      Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System or next generation model
      Cordis Cypher® Sirolimus-eluting Coronary Stent, Cordis Cypher Select® Sirolimus-eluting
      Coronary Stent or next generation model

      Primary Objective: To compare overall stent thrombosis rate of the Endeavor® Zotarolimus
      Eluting Coronary Stent System versus the Cypher® Sirolimus-eluting Coronary Stent in a
      patient population requiring stent implantation

      Secondary Objective: To compare the composite endpoint of total death or cardiac death
      combined with the number of patients with all non-fatal myocardial infarctions as well as
      the number of patients with large non-fatal myocardial infarctions for Endeavor® Zotarolimus
      Eluting Coronary Stent System versus the Cypher® Sirolimus-eluting Coronary Stent in a
      patient population requiring stent implantation.

      To assess the safety and efficacy in patient subgroups with specific demographics, clinical
      indications and/or vessel- or lesion characteristics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>To Compare Overall Definite or Probable Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System Versus the Cypher® Sirolimus-eluting Coronary Stent in a Patient Population Requiring Stent Implantation</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Definite or probable stent thrombosis rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composites of (Cardiac) Death and (Large) Non-fatal Myocardial Infarctions</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Total death and large non-fatal myocardial infarctions Total death and non-fatal myocardial infarctions Cardiac death and large non-fatal MI Cardiac death and non-fatal myocardial infarctions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8709</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cordis Cypher® Sirolimus-eluting Coronary Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stent</intervention_name>
    <description>Stent implantation</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stent</intervention_name>
    <description>Stent implantation</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Cordis Cypher® Sirolimus-eluting Coronary Stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is &gt; 18 years of age (or minimum age as required by local regulations).

          2. The patient has consented to participate and has authorized the collection and
             release of his medical information by signing the &quot;Patient Informed Consent Form&quot;.

          3. All lesions requiring interventions (target lesions - one to a maximum of four) in
             one or more native coronary arteries are amendable for implantation of one or more
             Endeavor® Zotarolimus Eluting Coronary Stent System or Cypher® Sirolimus-eluting
             Coronary Stent*.

          4. Patient indication, lesion length and vessel diameter of the target lesion(s) are
             according to the 'Indications for Use' as mentioned in the 'Instructions for Use'
             that comes with every Endeavor® Zotarolimus Eluting Coronary Stent System and Cypher®
             Sirolimus-eluting Coronary Stent. Patients should qualify for both systems before
             randomization*.

          5. The patient is willing and able to cooperate with study procedures and required
             follow up visits.

        Exclusion Criteria:

          1. Women with known pregnancy or who are lactating.

          2. Planned elective surgery necessitating discontinuation of clopidogrel within the
             regular planned period of clopidogrel administration.

          3. Patients expected not to be compliant with the anti-platelet and/or anticoagulation
             therapy regimen.

          4. Previous brachy-therapy.

          5. Previous implantation of a drug eluting stent.

          6. Previous implantation of a bare metal stent in the preceding year.

          7. Simultaneous or planned intervention other non cardiac vessels including but not
             limited to renal artery or carotid artery.

          8. Current medical condition with a life expectancy of less than 3 years.

          9. Manifest acute severe heart failure (Killip class III-IV).

         10. The patient is currently, and during the first 3 years of the PROTECT trial,
             participating in another investigational device or drug study that clinically
             interferes with the PROTECT-study endpoints; or requires coronary angiography or
             other coronary artery imaging procedures. The patient may only be enrolled in the
             PROTECT-study once.

         11. Patients with medical conditions that preclude the follow-up as defined in the
             protocol or that otherwise limits participation in this study.

         12. Patients on warfarin or similar anti-coagulant therapy.

         13. Patients with hypersensitivity or allergies to one of the drugs or components
             indicated in the Instructions for Use of either stents.

         14. Patients who are judged to have a lesion that prevents complete inflation of an
             angioplasty balloon.

         15. Patients in whom anti-platelet and/or anticoagulation therapy is contraindicated.

         16. Transplant patients.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edoardo Camenzind, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Geneva, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Mauri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital, US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William O'Neill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami Miller School of Medicine, US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Patrick W. Serruys, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC, Rotterdam, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Philippe Gabriel Steg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Département de Cardiologie, Hôpital Bichat-Claude Bernard, Assistance Publique - Hôpitaux de Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Wijns, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>O.L.V. Hospital, Aalst, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>196 enrolling sites Worldwide</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Camenzind E, Wijns W, Mauri L, Boersma E, Parikh K, Kurowski V, Gao R, Bode C, Greenwood JP, Gershlick A, O'Neill W, Serruys PW, Jorissen B, Steg PG; PROTECT Steering Committee and Investigators. Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. Am Heart J. 2009 Dec;158(6):902-909.e5. doi: 10.1016/j.ahj.2009.10.002.</citation>
    <PMID>19958855</PMID>
  </reference>
  <results_reference>
    <citation>Camenzind E, Wijns W, Mauri L, Kurowski V, Parikh K, Gao R, Bode C, Greenwood JP, Boersma E, Vranckx P, McFadden E, Serruys PW, O'Neil WW, Jorissen B, Van Leeuwen F, Steg PG; PROTECT Steering Committee and Investigators. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet. 2012 Oct 20;380(9851):1396-405. doi: 10.1016/S0140-6736(12)61336-1. Epub 2012 Aug 27.</citation>
    <PMID>22951082</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <lastchanged_date>November 3, 2014</lastchanged_date>
  <firstreceived_date>May 21, 2007</firstreceived_date>
  <firstreceived_results_date>September 17, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Eluting Stents</keyword>
  <keyword>Interventional Cardiology</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>8709 patients were randomized from May 2007 until December 2008 in 196 participating hospitals in 36 countries across five continents.</recruitment_details>
      <pre_assignment_details>80 patients were excluded because there was no validly signed consent available during monitoring and 2 patients retracted their consent before the procedure, resulting in a total of 8709 patients randomised.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>E-ZES</title>
          <description>Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System
Stent : Stent implantation</description>
        </group>
        <group group_id="P2">
          <title>C-SES</title>
          <description>Cordis Cypher® Sirolimus-eluting Coronary Stent
Stent : Stent implantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4357"/>
                <participants group_id="P2" count="4352"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4181"/>
                <participants group_id="P2" count="4159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="193"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="193"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention to treat analysis has been used.</population>
      <group_list>
        <group group_id="B1">
          <title>E-ZES</title>
          <description>Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System
Stent : Stent implantation</description>
        </group>
        <group group_id="B2">
          <title>C-SES</title>
          <description>Cordis Cypher® Sirolimus-eluting Coronary Stent
Stent : Stent implantation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="4357"/>
                <measurement group_id="B2" value="4352"/>
                <measurement group_id="B3" value="8709"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2428"/>
                <measurement group_id="B2" value="2468"/>
                <measurement group_id="B3" value="4896"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1929"/>
                <measurement group_id="B2" value="1884"/>
                <measurement group_id="B3" value="3813"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="62.3" spread="10.6"/>
                <measurement group_id="B2" value="62.1" spread="10.7"/>
                <measurement group_id="B3" value="62.2" spread="10.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1017"/>
                <measurement group_id="B2" value="1044"/>
                <measurement group_id="B3" value="2061"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3340"/>
                <measurement group_id="B2" value="3308"/>
                <measurement group_id="B3" value="6648"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Europe</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3180"/>
                <measurement group_id="B2" value="3179"/>
                <measurement group_id="B3" value="6359"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>South Asia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="623"/>
                <measurement group_id="B2" value="622"/>
                <measurement group_id="B3" value="1245"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>North America</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="115"/>
                <measurement group_id="B2" value="115"/>
                <measurement group_id="B3" value="230"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>South America</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="50"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Australia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="207"/>
                <measurement group_id="B2" value="207"/>
                <measurement group_id="B3" value="414"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>New Zealand</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="43"/>
                <measurement group_id="B2" value="42"/>
                <measurement group_id="B3" value="85"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Middle East</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="164"/>
                <measurement group_id="B2" value="162"/>
                <measurement group_id="B3" value="326"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Compare Overall Definite or Probable Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System Versus the Cypher® Sirolimus-eluting Coronary Stent in a Patient Population Requiring Stent Implantation</title>
        <description>Definite or probable stent thrombosis rate.</description>
        <time_frame>3 years</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>E-ZES</title>
            <description>Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System
Stent : Stent implantation</description>
          </group>
          <group group_id="O2">
            <title>C-SES</title>
            <description>Cordis Cypher® Sirolimus-eluting Coronary Stent
Stent : Stent implantation</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4357"/>
                  <measurement group_id="O2" value="4352"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>To Compare Overall Definite or Probable Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System Versus the Cypher® Sirolimus-eluting Coronary Stent in a Patient Population Requiring Stent Implantation</title>
            <description>Definite or probable stent thrombosis rate.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="75"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composites of (Cardiac) Death and (Large) Non-fatal Myocardial Infarctions</title>
        <description>Total death and large non-fatal myocardial infarctions Total death and non-fatal myocardial infarctions Cardiac death and large non-fatal MI Cardiac death and non-fatal myocardial infarctions</description>
        <time_frame>3 years</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>E-ZES</title>
            <description>Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System
Stent : Stent implantation</description>
          </group>
          <group group_id="O2">
            <title>C-SES</title>
            <description>Cordis Cypher® Sirolimus-eluting Coronary Stent
Stent : Stent implantation</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4357"/>
                  <measurement group_id="O2" value="4352"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Composites of (Cardiac) Death and (Large) Non-fatal Myocardial Infarctions</title>
            <description>Total death and large non-fatal myocardial infarctions Total death and non-fatal myocardial infarctions Cardiac death and large non-fatal MI Cardiac death and non-fatal myocardial infarctions</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Total death and large non-fatal myocardial infarct</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="225"/>
                  <measurement group_id="O2" value="255"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total death and non-fatal myocardial infarctions</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="331"/>
                  <measurement group_id="O2" value="360"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cardiac death and large non-fatal MI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="157"/>
                  <measurement group_id="O2" value="174"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cardiac death and non-fatal MI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="265"/>
                  <measurement group_id="O2" value="282"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Target lesion revascularization</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="249"/>
                  <measurement group_id="O2" value="156"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stroke</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="77"/>
                  <measurement group_id="O2" value="72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Bleeding events</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="201"/>
                  <measurement group_id="O2" value="184"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>E-ZES</title>
          <description>Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System
Stent : Stent implantation</description>
        </group>
        <group group_id="E2">
          <title>C-SES</title>
          <description>Cordis Cypher® Sirolimus-eluting Coronary Stent
Stent : Stent implantation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="579" subjects_at_risk="4357"/>
                <counts group_id="E2" subjects_affected="507" subjects_at_risk="4352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>MACCE (major adverse cardiac and cerebrovascular event</sub_title>
                <counts group_id="E1" events="579" subjects_affected="579" subjects_at_risk="4357"/>
                <counts group_id="E2" events="507" subjects_affected="507" subjects_at_risk="4352"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4.6</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="201" subjects_at_risk="4357"/>
                <counts group_id="E2" subjects_affected="184" subjects_at_risk="4352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="201" subjects_affected="201" subjects_at_risk="4357"/>
                <counts group_id="E2" events="184" subjects_affected="184" subjects_at_risk="4352"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>For any publication or presentation of the Protected Materials or any portion thereof, a manuscript of the paper, abstract or other materials will be provided by Consultant to Sponsor for its approval at least sixty (60) days for manuscripts and thirty (30) days for presentations prior to outside submission. Medtronic shall have the right to request reasonable modifications of any manuscript or other materials to be published or presented.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Frank van Leeuwen, Director Clinical Research Coronary and Renal Denervation</name_or_title>
      <organization>Medtronic Bakken Research Center</organization>
      <phone>+31 43 3566622</phone>
      <email>frank.van.leeuwen@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
